Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/67988

Memory improvement in the AβPP/PS1 mouse model of familial Alzheimer's disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes
Armand-Ugón, Mercedes; Asó, Ester; Moreno Castro, Jesús; Riera i Codina, Miquel; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Ferrer, Isidro (Ferrer Abizanda)
Neuroprotection of erythropoietin (EPO) following long-term administration is hampered by the associated undesirable effects on hematopoiesis and body weight. For this reason, we tested carbamylated-EPO (CEPO), which has no effect on erythropoiesis, and compared it with EPO in the AβPP/PS1 mouse model of familial Alzheimer's disease. Groups of 5-month-old wild type (WT) and transgenic mice received chronic treatment consisting of CEPO (2,500 or 5,000 UI/kg) or EPO (2,500 UI/kg) 3 days/week for 4 weeks. Memory at the end of treatment was assessed with the object recognition test. Microarray analysis and quantitative-PCR were used for gene expression studies. No alterations in erythropoiesis were observed in CEPO-treated WT and AβPP/PS1 transgenic mice. EPO and CEPO improved memory in AβPP/PS1 animals. However, only EPO decreased amyloid-β (Aβ) plaque burden and soluble Aβ40. Microarray analysis of gene expression revealed a limited number of common genes modulated by EPO and CEPO. CEPO but not EPO significantly increased gene expression of dopamine receptors 1 and 2, and adenosine receptor 2a, and significantly down-regulated adrenergic receptor α1D and gastrin releasing peptide. CEPO treatment resulted in higher protein levels of dopamine receptors 1 and 2 in WT and AβPP/PS1 animals, whereas the adenosine receptor 2a was reduced in WT animals. The present results suggest that the improved behavior observed in AβPP/PS1 transgenic mice after CEPO treatment may be mediated, at least in part, by the observed modulation of the expression of molecules involved in neurotransmission.
-Malaltia d'Alzheimer
-Receptors de neurotransmissors
-Eritropoetina
-Alzheimer's disease
-Neurotransmitter receptors
-Erythropoietin
(c) Armand-Ugón, Mercedes et al., 2015
Artículo
Artículo - Versión publicada
IOS Press
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Armand-Ugón, Mercedes; Asó, Ester; Moreno Castro, Jesús; Riera i Codina, Miquel; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Ferrer, Isidro (Ferrer Abizanda)
Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
Asó, Ester; Sànchez, Àlex (Sànchez Pla); Vegas Lozano, Esteban; Maldonado, Rafael, 1961-; Ferrer, Isidro (Ferrer Abizanda)
López González, Irene; Schlüter, Agatha; Asó, Ester; Garcia Esparcia, Paula; Ansoleaga, Belén; Llorens Torres, Franc; Carmona Murillo, Margarita; Moreno Castro, Jesús; Fuso, Andrea; Portero Otin, Manuel; Pamplona, Reinald; Pujol Onofre, Aurora; Ferrer, Isidro (Ferrer Abizanda)